Tofacitinib

Janus kinase inhibitor with JAK1 and JAK3 activity · also known as Xeljanz, Xeljanz XR

Broad JAK inhibitor represented in MCAS by a two-patient report, without a comparison group or measured mast-cell effect.

How it relates to mast cells: MCAS patients
Types of studies cited: Case report
Approved in the US for: rheumatoid arthritis after inadequate response or intolerance to TNF blockers, psoriatic arthritis after inadequate response or intolerance to TNF blockers, ankylosing spondylitis after inadequate response or intolerance to TNF blockers, ulcerative colitis after inadequate response or intolerance to TNF blockers, polyarticular-course juvenile idiopathic arthritis after TNF-blocker failure
Catalog context: Emerging / refractory evidence

What this relationship means: Studied in people diagnosed with mast cell activation syndrome. Current evidence consists of case reports, uncontrolled series, or retrospective review rather than randomised comparisons — so it establishes that people have taken it, not that it worked.

Mechanism of action

Tofacitinib inhibits Janus-kinase signalling, with activity centred on JAK1 and JAK3. JAK pathways transmit signals from numerous cytokine receptors in many immune and blood-cell populations. The case report proposed that blocking downstream JAK signalling might bypass heterogeneous upstream abnormalities described by its authors, but it did not show that tofacitinib directly stabilizes mast cells.

The entire direct MCAS evidence object is a report of two patients. The publication records clinical observations after exposure, without a control group or a prospective standardized mast-cell endpoint. Its diagnostic framing also predates more recent disputes over MCAS definitions. The entry therefore records direct patient exposure and a case-series study design while keeping the evidence object visibly case-level.

The current US label is for specified inflammatory diseases after inadequate response or intolerance to TNF blockers. Its boxed-warning population and broad immunosuppressive mechanism are materially different from a mast-cell-selective investigational program. MCAS is neither an approved indication nor a randomized trial population in the cited evidence.

Sources

Successful targeted treatment of mast cell activation syndrome with tofacitinib Peer-reviewed study 2017 PMID 28382662 · link checked 21 Aug 2026
XELJANZ, XELJANZ XR, and XELJANZ oral solution current US prescribing information Drug label · link checked 21 Aug 2026

What this evidence cannot establish

The direct MCAS evidence is a two-patient report from 2017 with no comparator, blinding, standardized prospective outcome assessment, or measured effect on mast cells. Two clinical histories cannot separate drug attribution from time, selection, concurrent care, or diagnostic assumptions, and JAK signalling occurs across many immune-cell types. The accessible primary record does not identify the treating clinician precisely enough for the site's specialist-use tag, so this entry carries none. Tofacitinib is a broad systemic immunomodulator whose current boxed warning covers serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis; its approved indications do not include MCAS.

What this page does not say

No dosing, and no claim that this works. The entry describes a published mechanism, the cited study types, and what those studies cannot establish — nothing further. Why the site is built this way.

Recently verified. Verified 21 Aug 2026